This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

49/100

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Background Intrinsic capacity (IC) is a recent key concept proposed by the World Health Organization (WHO) based on aspects of functional ability (both physical and mental) rather than the presence or absence of diseases, with a potential to predict several health outcomes. Objective To explore associations between IC and cognitive function (prospectively), and between IC and plasma p-tau181 (cross-sectionally and prospectively) among community-dwelling older adults. Methods Observational study with 491 subjects ≥70 years (67.4 % female, mean 75.3 years, SD=4.4), participants from the Multidomain Alzheimer Preventive Trial (MAPT).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Giudici, K. V., de Souto Barreto, P., Cantet, C., Zetterberg, H., Blennow, K., Vellas, B., et al. (2025). Associations between intrinsic capacity, plasma p-tau181 and cognitive function over a 5-year follow-up among community-dwelling older adults: a secondary analysis of the MAPT Study. The Journal of frailty & aging. https://doi.org/10.1016/j.tjfa.2025.100064

Vancouver

Giudici KV, de Souto Barreto P, Cantet C, Zetterberg H, Blennow K, Vellas B, et al. Associations between intrinsic capacity, plasma p-tau181 and cognitive function over a 5-year follow-up among community-dwelling older adults: a secondary analysis of the MAPT Study. The Journal of frailty & aging. 2025. doi:10.1016/j.tjfa.2025.100064. PMID: 40601428.

BibTeX

@article{giudici2025-40601428,
  author  = {Giudici, K. V. and de Souto Barreto, P. and Cantet, C. and Zetterberg, H. and Blennow, K. and Vellas, B. and {MAPT/DSA group}},
  title   = {{Associations between intrinsic capacity, plasma p-tau181 and cognitive function over a 5-year follow-up among community-dwelling older adults: a secondary analysis of the MAPT Study}},
  journal = {The Journal of frailty \& aging},
  year    = {2025},
  doi     = {10.1016/j.tjfa.2025.100064},
  pmid    = {40601428},
  url     = {https://doi.org/10.1016/j.tjfa.2025.100064}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Objective To explore associations between IC and cognitive function (prospectively), and between IC and plasma p-tau181 (cross-sectionally and prospectively) among community-dwelling older adults.
Methods Observational study with 491 subjects ≥70 years (67.4 % female, mean 75.3 years, SD=4.4), participants from the Multidomain Alzheimer Preventive Trial (MAPT).
IC domains (locomotion, cognition, psychological, vitality) were combined into a 0-100 score.
Alternative classification was based on the number of domains' abnormalities.

Why it matters

This observational analysis of the MAPT study explored links between intrinsic capacity, plasma p-tau181 and cognitive function over 5 years in community-dwelling older adults. It examines associations over time and does not test any treatment, cure or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcross-sectional
Participants491
Evidence strengthLow

How this study scored 49/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Journal of frailty & aging)
Journal's citation record	0 / 4	The Journal of Frailty & Aging: journal h-index 48 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	491 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Bruno J. Vellas: h-index 135 (OpenAlex, whole career)
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 11 institution(s) in 4 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40601428)
Free to read	2 / 2	Free to read
Total	49 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →